Literature DB >> 26272491

Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Antoni Ribas1.   

Abstract

UNLABELLED: Adaptive immune resistance is a process in which the cancer changes its phenotype in response to a cytotoxic or proinflammatory immune response, thereby evading it. This adaptive process is triggered by the specific recognition of cancer cells by T cells, which leads to the production of immune-activating cytokines. Cancers then hijack mechanisms developed to limit inflammatory and immune responses and protect themselves from the T-cell attack. Inhibiting adaptive immune resistance is the mechanistic basis of responses to PD-1 or PD-L1-blocking antibodies, and may be of relevance for the development of other cancer immunotherapy strategies. SIGNIFICANCE: Several new immunotherapy strategies to treat cancer are based on inhibiting processes through which cancer adapts and evades from an immune response. Recognizing the specific adaptive resistance mechanisms in each case is likely to allow the personalized development of immunotherapies tailored to block how a particular cancer protects itself from the immune system. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26272491      PMCID: PMC4560619          DOI: 10.1158/2159-8290.CD-15-0563

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  46 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

2.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

5.  CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Authors:  Rong Rong Huang; Jason Jalil; James S Economou; Bartosz Chmielowski; Richard C Koya; Stephen Mok; Hooman Sazegar; Elizabeth Seja; Arturo Villanueva; Jesus Gomez-Navarro; John A Glaspy; Alistair J Cochran; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Immunoediting of cancers may lead to epithelial to mesenchymal transition.

Authors:  Keith L Knutson; Hailing Lu; Brad Stone; Jennifer M Reiman; Marshall D Behrens; Christine M Prosperi; Ekram A Gad; Arianna Smorlesi; Mary L Disis
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

8.  Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.

Authors:  Tobias Bald; Jennifer Landsberg; Dorys Lopez-Ramos; Marcel Renn; Nicole Glodde; Philipp Jansen; Evelyn Gaffal; Julia Steitz; Rene Tolba; Ulrich Kalinke; Andreas Limmer; Göran Jönsson; Michael Hölzel; Thomas Tüting
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

9.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  209 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  The Evolution of Adjuvant Therapy for Melanoma.

Authors:  Justine V Cohen; Elizabeth I Buchbinder
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

4.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

5.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Authors:  Ila Datar; Miguel F Sanmamed; Jun Wang; Brian S Henick; Jungmin Choi; Ti Badri; Weilai Dong; Nikita Mani; Maria Toki; Luis D Mejías; Maria D Lozano; Jose Luis Perez-Gracia; Vamsidhar Velcheti; Matthew D Hellmann; Justin F Gainor; Kristen McEachern; David Jenkins; Konstantinos Syrigos; Katerina Politi; Scott Gettinger; David L Rimm; Roy S Herbst; Ignacio Melero; Lieping Chen; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2019-05-03       Impact factor: 12.531

6.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 7.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 8.  Combination immunotherapy strategies for glioblastoma.

Authors:  Hok Yee Chan; John Choi; Christina Jackson; Michael Lim
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 9.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

Review 10.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.